FIELD: pharmaceutical industry.
SUBSTANCE: present group of inventions refers to an immunogenic lyophilized composition, an immunogenic dissolved composition and use thereof for producing a vaccine. Immunogenic lyophilized composition contains a virus-based material, polyvinylpyrrolidone, copovidone and/or a mixture thereof, sugars, amino acids, pharmaceutically acceptable salts, wherein at least one of said salts is a phosphate salt, a pharmaceutically acceptable buffer.
EFFECT: such compositions can be used as vaccines, preferably for treatment and/or prevention of cancer diseases, infectious diseases and/or autoimmune disorders.
25 cl, 2 dwg, 5 ex, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE VACCINE VIRUS LIQUID PREPARATIONS | 2015 |
|
RU2704485C2 |
| RECOMBINANT VIRAL VACCINE | 2007 |
|
RU2453335C2 |
| LYOPHILISED COMPOSITION FOR INDUCING IMMUNE RESPONSE TO FLAVIVIRUS, COMPOSITION AND METHOD FOR PREPARING IT | 2007 |
|
RU2541784C2 |
| METHOD OF REDUCTION AND PURIFICATION OF ORTHOPOXVIRUS | 2010 |
|
RU2560976C2 |
| CHEMICALLY SPECIFIED STABILISER | 2006 |
|
RU2409350C2 |
| STABLE AQUEOUS COMPOSITIONS OF PROTEIN MIA/CD-RAP | 2011 |
|
RU2588658C2 |
| STABLE AQUEOUS PROTEIN COMPOSITIONS OF MIA/CD-RAP | 2011 |
|
RU2739078C2 |
| STABILISING EXCIPIENT FOR VACCINE WITH INACTIVATED WHOLE VIRUSES | 2010 |
|
RU2560675C2 |
| PRODUCTION OF POX VIRUSES AND COMPOSITION OF POX VIRUSES | 2013 |
|
RU2581910C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
